• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·VIVOBIOT.BO
Share

Vivo Bio Tech Limited Stocks

₹ 20.94Last Updated 29.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 4.16M

₹ 20.94
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vivo Bio Tech Ltd. specializes in delivering comprehensive services for pharmaceutical research and development. The company's diverse offerings encompass both in-vivo and in-vitro toxicology assessments, in-depth pharmacological investigations, pharmacokinetic and toxicokinetic analyses, genotoxicity screening, and a variety of analytical services. The firm conducts its operations through distinct Bio Agriculture and Industrial segments. Founded by Vish Kompella on February 12, 1987, the enterprise maintains its primary headquarters in Hyderabad, India.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 01:08

The assets of the "AI-Nostradamus" fund fell to $10 billion following the sale of part of its portfolio

30.07.2026 23:45

OpenAI has lowered the price of GPT-5.6 for budget-conscious customers

30.07.2026 23:38

UEFA has threatened to boycott FIFA tournaments over plans to sell World Cup rights to investors

30.07.2026 23:35

The yuan rose to its highest level since 2023 amid a decline in the dollar following the Fed meeting

30.07.2026 22:48

SpaceX has been awarded a $1.6 billion contract by the U.S. Space Force

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026